IOL Chemicals & Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹795 Cr +40% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
IC

IOL Chemicals & Pharmaceuticals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

IOL Chemicals & Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹580Cr
+10.9% YoY
+2.1% QoQ
Net profit
₹21Cr
0% YoY
−30% QoQ
Margin
10%
+1 pp YoY
0 pp QoQ
Price₹170
Market cap₹4.8K Cr
P/E32.8

The short version

The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27). Company expects 10% to 15% growth in top line for FY '27.

From IOL Chemicals & Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27).
  • Bottom-line growth is anticipated between 15% to 20%.
  • The focus is on increasing exports, especially of pharmaceutical products, including efforts to boost the non-ibuprofen (non-ibu) API share.
  • Capacity utilization is high for pharma (above 90%), except paracetamol which is expanding; chemicals utilization is near 200%.
  • The paracetamol segment is expected to be a key growth driver, alongside metformin and the shift of non-ibu domestic sales to regulated markets.
  • New capacities are being planned, with ongoing capex of around INR 150-200 crores annually.

2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY '26 capex budget was around INR 150 crores; actual expected slightly lower (~INR 130-135 crores).
  • Approximately 60% of FY '26 capex directed towards growth, and 40% towards infrastructure development and automation.
  • For FY '27, the company plans a similar level of capex (~INR 150-200 crores), though final plans are yet to be finalized.
  • Capex aims to support increased capacity, particularly expanding key products like paracetamol and non-ibuprofen APIs.

2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant points from the discussion related to business momentum and growth include: - The company reported revenue growth and strong capacity utilization (ibuprofen plant running over 90% capacity). - They expect to achieve revenue of around INR600 crores in Q4. - Focus on expanding products, increasing non-ibuprofen API share, and regulated market exports. - Capex plans of approximately INR150-200 crores aimed at growth and capacity expansion.

2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 results — key figures

IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue580523+10.9%568+2.1%
Operating profit (EBITDA)5747+21.3%570%
Operating margin10%9%+1 pp10%0 pp
Profit before tax28280%41-31.7%
Net profit (PAT)21210%30-30%
EPS (₹)0.700.700%1.02-31.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹795 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

IOL Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 results?

The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27). Company expects 10% to 15% growth in top line for FY '27.

What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?

IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹4,797 Cr. Investors should review the full earnings analysis for detailed insights.

Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?

FY '26 capex budget was around INR 150 crores; actual expected slightly lower (~INR 130-135 crores).

Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.